Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript
Mesa Laboratories NASDAQ: MLAB reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control business and accelerate product development in Biopharmaceutical Development.
Mesa Laboratories, Inc. (MLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Mesa Labs (MLAB) came out with quarterly earnings of $2.32 per share, missing the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $2.83 per share a year ago.
Mesa Labs (MLAB) came out with quarterly earnings of $2.23 per share, missing the Zacks Consensus Estimate of $2.75 per share. This compares to earnings of $2.77 per share a year ago.
Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Mesa Labs (MLAB) came out with quarterly earnings of $2.67 per share, beating the Zacks Consensus Estimate of $2.45 per share. This compares to earnings of $2.02 per share a year ago.
Mesa Labs (MLAB) came out with quarterly earnings of $2.45 per share, missing the Zacks Consensus Estimate of $2.48 per share. This compares to earnings of $1.91 per share a year ago.
Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).